Geographic Atrophy: Understanding Current Therapies
Provider: Mivision
Activity Outline
Geographic atrophy (GA) is one of two forms of advanced
age-related macular degeneration (AMD) that can cause irreversible vision loss.1
Unlike its counterpart – neovascular AMD (nAMD) – until now there has been a huge
unmet need for treatment for this potentially blinding condition.
Australia’s Therapeutic Goods Administration (TGA) is currently assessing an application by Apellis for the approval of pegcetacoplan injection (Syfovre) for the treatment of geographic atrophy and there are more treatments for this disease in the pipeline. In this article, Dr Amy Cohn looks at the correlation between progression of GA lesions and changes in visual function. She explores the rationale behind the United States Food and Drug Administration (FDA) approval of these medications, and discusses novel assessments of visual function in AMD patients.
Learning Objectives
- Realise the correlation between progression of GA lesions and changes in visual function
- Understand the treatment goals
- Be aware of treatment outcomes from recent studies
- Be aware of a range of tools for assessing visual function in GA
Max CPD hours awarded: 1
Session Information
| Name |
|---|
| Geographic Atrophy: Understanding Current Therapies |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 0.5 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 1 |